Physician profile
Robert Brunst
NPI 1639257546
$2,449.23
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $1,020 · 2021: $370.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $376.58 | 2019-2021 | |
| Allergan, INC. | $298.12 | 2019-2020 | |
| Abbvie INC. | $239.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $196.50 | 2019-2021 | |
| Amarin Pharma, INC. | $193.26 | 2019-2021 | |
| Pfizer INC. | $158.62 | 2019-2020 | |
| Amgen INC. | $155.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $149.10 | 2019-2021 | |
| Eisai INC. | $113.66 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $107.83 | 2019-2020 | |
| Astellas Pharma US INC | $86.13 | 2019-2020 | |
| Lilly USA, LLC | $56.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $43.97 | 2019 | |
| Ibsa Pharma INC. | $38.82 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.91 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $25.61 | 2021 | |
| Aytu Biopharma, INC. | $21.28 | 2019 | |
| Neotract INC. | $20.53 | 2019 | |
| Novo Nordisk INC | $19.18 | 2019 | |
| Genentech USA, INC. | $17.02 | 2019 | |
| Horizon Therapeutics Plc | $16.24 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.58 | 2019 | |
| Dermira, INC. | $12.96 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brunst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.